Celcuity

Celcuity Net Change in Cash

The Net Change in Cash of Celcuity (CELC) as of Nov 11, 2026 is 143.19 M USD. In the previous year, Net Change in Cash was -8.15 M USD — a change of -1,857.35% (higher).

Net Change in Cash

143.19 MUSD

YoY

-1,857.35%

Last updated:

Net Change in Cash of Celcuity is 2025 143.19 M USD. Net Change in Cash of Celcuity was 2024 -8.15 M USD. It decreases by -1,857.35% higher compared to the previous year.

The Celcuity Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
13.25 M USD
Jan 1, 2019
2.79 M USD
Jan 1, 2020
-7.10 M USD
Jan 1, 2021
72.65 M USD
Jan 1, 2022
-59.71 M USD
Jan 1, 2023
6.09 M USD
Jan 1, 2024
-8.15 M USD
Jan 1, 2025
143.19 M USD
The Celcuity Net Change in Cash history
YEARNet Change in CashYoY
143.19 MUSD-1,857.35%
-8.15 MUSD-233.77%
6.09 MUSD-110.20%
-59.71 MUSD-182.20%
72.65 MUSD-1,123.64%
-7.10 MUSD-354.34%
2.79 MUSD-78.95%
13.25 MUSD-512.08%
-3.22 MUSD-507.62%
789,108.00USD-71.25%
2.74 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Net Change in Cash of Celcuity is 143.19 M USD in 2025.

Net Change in Cash of Celcuity changed from -8.15 M USD to 143.19 M USD, representing a -1,857.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Celcuity since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Celcuity

All Key Metrics — Celcuity